Ryght, Inc.

Ryght, Inc. is a US-based company specializing in AI-driven solutions for clinical trial management, focusing on enhancing site selection and feasibility analysis through innovative technology and data-driven insights. Founded in 2023, Ryght, Inc. is headquartered in Anaheim, US, and specializes in providing AI solutions for clinical trials.

The company has completed 2 deals so far, with the latest being a Seed funding round of USD 3. 000 mn in June 2025, led by Foothill Ventures and supported by other investors including AIX Ventures and Iaso Ventures. The founder's background details are not disclosed, nor are any references to previous companies he/she may have founded. Ryght Inc.

specializes in advanced AI-powered solutions for clinical trial management, particularly focusing on site selection and feasibility analysis. Their core offering, the Ryght AI platform, utilizes generative AI technology to help sponsors and Contract Research Organizations (CROs) efficiently identify, select, and activate clinical research sites that align with specific study protocols. The platform rapidly assesses study requirements and connects users with high-potential research sites globally, thereby streamlining the trial process. Ryght's AI Site Twins serve as digital replicas of clinical research sites, capturing detailed operational characteristics and historical performance metrics, which enhance decision-making and optimize study outcomes.

The company's solutions cater primarily to biopharmaceutical sponsors and CROs, with a customer base that spans various international markets, including North America, Europe, and Asia. Ryght Inc. operates on a subscription-based revenue model, providing its clients with access to its AI platform and related services. Clients, which include biopharmaceutical companies and CROs, typically engage in partnerships to leverage the platform for site selection and feasibility assessments.

Transactions are structured around annual subscriptions, allowing access to the extensive network of AI Site Twins and associated analytical tools. The pricing plans are designed to accommodate varying levels of service usage, with specific plans tailored to the distinct needs of sponsors and CROs. Ryght's offerings position it as a valuable partner in accelerating clinical trial processes, with a focus on delivering measurable improvements in efficiency and site performance. In June 2025, Ryght, Inc.

raised USD 3. 000 mn in Seed funding led by new investor Foothill Ventures, with participation from AIX Ventures and several others. The company plans to use this funding to expand its network of clinical trial sites, enhance its artificial intelligence capabilities, and improve site selection and activation processes. As part of its growth strategy, Ryght aims to launch new features for its AI platform and explore opportunities in new geographic regions, specifically targeting expansion into Europe and Asia by the end of 2026.